rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PRME
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Prime Medicine closes $143.7M public offering at $3.50/share
      Nov 12Investing.comPRME
      Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
      Nov 12Yahoo FinancePRME
      Cathie Wood’s ARK sells Absci stock, buys Prime Medicine
      Nov 12Investing.comABSIPRME
      Prime Medicine prices $125M stock offering at $3.50/share
      Nov 11Investing.comPRME
      Prime Medicine commences $125 million public stock offering
      Nov 10Investing.comPRME
      Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
      Nov 10Yahoo FinancePRME
      Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?
      Oct 29Yahoo FinancePRME
      Why Prime Medicine’s Thin Float and Heavy Short Interest Raise Breakout Risk
      Oct 12Investing.comPRME
      Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
      Oct 12Yahoo FinancePRME
      Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Prime Medicine, Inc. (PRME)

      Tipranks Press Release.

      Oct 6The Globe and MailPRAXPRME
      Prime Medicine stock rating maintained at Market Outperform by Citizens
      Oct 6Investing.comPRME
      Prime Medicine doses first patient in Wilson disease gene therapy trial
      Oct 6Investing.comPRME
      Prime Medicine, Inc. (PRME) Gets a Buy from H.C. Wainwright

      Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailPRME
      Citizens reiterates Prime Medicine stock rating on gene editing capabilities
      Sep 28Investing.comPRME
      Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Edgewise Therapeutics (EWTX)

      Tipranks Press Release.

      Sep 26The Globe and MailEWTXPRME
      Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME)

      Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.

      Sep 25Seeking AlphaPRME
      Prime Medicine Gets FDA Green Light for Gene Editing Study - Prime Medicine (NASDAQ:PRME)

      The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.

      Sep 25BenzingaPRME
      Prime Medicine stock holds at outperform on FDA IND clearance
      Sep 25Investing.comPRME
      Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says
      Sep 25Yahoo FinancePRME
      12 Health Care Stocks Moving In Thursday's After-Market Session - Prime Medicine (NASDAQ:PRME), Onconetix

      Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix (NASDAQ:ONCO) stock rose

      Sep 24BenzingaONCOPRME
      Why is Prime Medicine stock surging today?
      Sep 24Investing.comPRME
      Prime Medicine receives FDA clearance for AATD gene therapy
      Sep 24Investing.comPRME
      Prime Medicine stock surges on FDA IND clearance
      Sep 24Investing.comPRME
      Prime Medicine at Morgan Stanley conference: editing push faces delivery test
      Sep 16Investing.comPRMEMS
      Prime Medicine at H.C. Wainwright conference: platform gains focus
      Sep 15Investing.comPRME
      Prime Therapeutics names Manmohan Mahajan chief financial officer
      Sep 10Yahoo FinancePRME
      Prime Medicine to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: Wells Fargo 21st Annual Healthcare Conference: Company management will host 1x1 meetings on Thursday, September 10, 2026, in Boston, MA.H.C. Wainwright 28th Annual Global Investment Conference: Fireside chat

      Sep 3Yahoo FinancePRME

      This is the newest page. Registered accounts read further back.